Related Experiment Videos
[Tissue polypeptide antigen in gynecological cancer]
Gan No Rinsho. Japan Journal of Cancer Clinics
|January 1, 1985
Summary
Tissue polypeptide antigen (TPA) shows elevated levels in cervical, corpus, and ovarian cancers, correlating with clinical progression. Immunohistochemistry confirms TPA presence in cancer cells, indicating its potential as a tumor marker.
Area of Science:
- Oncology
- Biochemistry
- Immunohistochemistry
Context:
- Gynecologic cancers present diagnostic challenges.
- Biomarker identification is crucial for early detection and monitoring.
- Tissue polypeptide antigen (TPA) is a potential tumor marker.
Purpose:
- To evaluate serum TPA, CEA, and IAP levels in cervical, corpus, and ovarian cancers.
- To assess the correlation of TPA levels with clinical course.
- To determine the cellular localization of TPA via immunohistochemistry.
Summary:
- Serum TPA levels were elevated in 39% of cervical cancer, 46% of corpus cancer, and 64% of ovarian cancer patients.
- TPA demonstrated a higher positive rate than CEA, with LAP levels comparable to TPA.
- TPA was detected in cancer cells but not in normal tissues, suggesting specificity.
Impact:
- TPA shows promise as a sensitive biomarker for gynecologic malignancies.
- Monitoring TPA levels may aid in tracking clinical progression.
- Immunohistochemical findings support TPA's role as a cancer-specific antigen.